Skip to main content
. 2024 Dec 17;50(6):e20240228. doi: 10.36416/1806-3756/e20240228

Table 3. Immune-mediated adverse events during consolidation therapy.

Adverse event Total n (%) Grade 1 n (%) Grade 2 n (%) Grade 3 n (%)
Pneumonitis 4 (12.9) 1 (3.2) 2 (6.4) 1 (3.2)
Hypothyroidism 3 (9.7) 1 (3.2) 2 (6.4) 0 (0.0)
Pruritus 1 (3.2) 1 (3.2) 0 (0.0) 0 (0.0)

The percentages presented in this Table were calculated using the total number of patients (N=31) as the denominator.